Navigation Links
deCODE Shows how Genetic Risk of Kidney Disease Frames Response to Environmental Risk Over Time
Date:7/29/2010

REYKJAVIK, Iceland, July 29, 2010 /PRNewswire-FirstCall/ -- Scientists at deCODE genetics and colleagues at Radboud University in the Netherlands today describe how the impact of a single letter variation in the sequence of the human genome (SNP) conferring risk of kidney disease varies with age and with the onset of other diseases. The study provides independent confirmation of the association made in an earlier study between a version of the the SNP, located on chromosome 16p12, and risk of chronic kidney disease (CKD). It also confirmed the link between the SNP and concentrations of serum creatinine (SCr), a key indicator of kidney function. But the deCODE team then used its detailed population-based data in Iceland to go further, demonstrating that the impact of the at-risk version SNP on risk of kidney disease and SCr increases with age and if carriers develop high blood pressure or type 2 diabetes. At the same time, the SNP was shown in a large Icelandic and Dutch case-control cohort to protect against the formation of kidney stones.

"The common diseases happen at the interface between genes and the environment, and this study offers a clear and medically useful example of this dynamic in action. This SNP is now a validated risk factor for kidney disease, but we have also shown how it can be made even more meaningful if looked at in the context of age and broader health history. It is directly adjacent to the gene econding uromodulin, or UMOD, the most abundant protein in human urine. It therefore appears that it confers risk by modulating how the kidneys adapt to age itself and to the accumulation of environmental insults, such as hypertension and diabetes, over time. We believe this mechanism may be a fruitful subject for further research aimed at preventing and treating kidney disease," said Kari Stefansson, deCODE's Executive Chairman and President of Research and senior author of the study.

The paper, "Association of variants at UMOD with chronic kidney disease and kidney stones - role of age and comorbid diseases," is published online in the open-access journal PLOS Genetics, at http://www.plosgenetics.org.

About deCODE

Headquartered in Reykjavik, Iceland, deCODE genetics is a global leader in analyzing and understanding the human genome. Using its unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer. deCODE employs its capabilities to develop DNA-based tests and personal genome scans to better understand individual risk and empower prevention. It also licenses its tests, intellectual property and analytical tools to partners, and provides comprehensive genotyping, sequencing and data analysis services to companies and research institutions around the globe. Through its CLIA- and CAP-certified laboratory deCODE offers DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE BreastCancer, for the common forms of breast cancer. Through its pioneering personal genome analysis service deCODEme(TM), deCODE enables individuals to better understand their risk of dozens of common diseases and to learn about their ancestry and other traits. Visit us on the web at http://www.decode.com; at http://www.decodediagnostics.com; at http://www.decodeme.com; and on our blog at http://www.decodeyou.com.

    Contacts:

    Edward Farmer
    +44(0)7796-010107
    edward.farmer@decode.is

    Gisli Arnason
    +354-570-1900
    info@decode.is


'/>"/>
SOURCE DeCODE Genetics Inc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
2. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
3. deCODE Launches a DNA-Based Test for Assessing Risk of Prostate Cancer on the Back of the Discovery of New Prostate Cancer Genes
4. deCODE Obesity Study Sheds Light on How Genetics Affects Risk and Onset of Common Diseases
5. deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer
6. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
7. deCODE and SGENE Consortium Discover Deletions in the Human Genome Linked to Risk of Schizophrenia
8. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
9. deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders
10. Major deCODE-led Study Underscores Role of the Brain in Obesity
11. A Milestone in Cancer Genetics: deCODE Discovers First Common Genetic Variants Affecting the Risk of Many Types of Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
(Date:4/19/2017)... 19, 2017  IRIDEX Corporation (Nasdaq: IRIX ... for the first quarter 2017 after the close of ... team will host a corresponding conference call beginning at ... Investors interested in listening to the conference call may ... or (703) 326-3030 for international callers, using conference ID: ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... Pitavastatin, a relatively new statin, ... not known to have significant interactions with antiretroviral therapy (ART). Among people ... and dampen inflammation in the bloodstream. , While lowering cholesterol and dampening inflammation ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... that over the last decade, student well-being has seriously declined. "When disenfranchised youth ... formal education, join the Islamic State to turn the historic multi-ethnic and multi-religious ...
(Date:4/24/2017)... ... 24, 2017 , ... Life of Purpose Treatment is proud to present “An ... held at 7:30 pm on May 10th at the University Auditorium. , This benefit ... will support the UF Collegiate Recovery Community (UFCRC). The concert will kick off the ...
(Date:4/23/2017)... ... April 23, 2017 , ... Altura ... the achievement of Cisco Select certification and SMB specialization. Altura is now ... , In earning the Select Certification, Altura fulfilled the training and exam ...
(Date:4/22/2017)... San Juan Capistrano (PRWEB) , ... April 22, 2017 , ... The San Juan ... have recently released a parenting report outlining the need for summer camps to provide physical ... , The Importance of Physical Activity In Summer Camps , With an increase in specialty ...
Breaking Medicine News(10 mins):